Posted by: SomaNews on: 12 Mar, 2010
Dainippon Sumitomo Pharma America, a US subsidiary of Dainippon Sumitomo Pharma (DSP), has reported that the FDA has accepted for review the lurasidone new drug application (NDA) for the treatment of patients with acute schizophrenia.
Posted by: SomaNews on: 12 Mar, 2010
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Posted by: SomaNews on: 12 Mar, 2010
The U.S. Food and Drug Administration today warned health care providers and consumers about counterfeit surgical mesh being distributed in the United States under the C. R. Bard/Davol brand name. Surgical mesh products are used to reinforce soft tissue where weakness exists.
Posted by: SomaNews on: 12 Mar, 2010
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.
Posted by: SomaNews on: 12 Mar, 2010
Should cannabis be legalised? This thorny political issue will be debated by teams of school children in a national competition designed to challenge the pupil’s scientific knowledge. The event is part of the Festival of Social Science organised by the Economic and Social Research Council (ESRC) and will be staged at the Royal Pharmaceutical Society of Great Britain.
Posted by: SomaNews on: 12 Mar, 2010
Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.
Posted by: SomaNews on: 12 Mar, 2010
ReportsandReports announce it will carry The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities Market Research Report in its Store.
Posted by: SomaNews on: 12 Mar, 2010
A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.
Posted by: SomaNews on: 12 Mar, 2010
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists.
Posted by: SomaNews on: 12 Mar, 2010
Automated reminder and follow-up calls for HPV vaccinations increase adherence rates from 5% to over 20%, according to a new white paper published by iReminder, LLC. The Scotland National Health Service is the leader in HPV vaccination compliance, with rates as high as 92% for the first dose and 87.8% for the second dose. The laggard is Mississippi, USA where HPV vaccination rates are as low as 15.8%.
Recent Comments